Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 14/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456469 | 0.84 | CYP1A2 (0.65) | CYP1A2GAAPDE4APDE7A | |
| SCHEMBL193469 | 0.81 | GAA (0.63) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL185651 | 0.79 | CYP1A2 (0.71) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL1715548 | 0.77 | CYP1A2 (0.73) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL24411044 | 0.77 | CYP1A2 (0.54) | CYP1A2GAAPDE4APDE7A | |
| SCHEMBL193553 | 0.77 | CYP1A2 (0.54) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL19127721 | 0.77 | CYP1A2 (0.54) | CYP1A2GAAPDE4APDE7A | |
| SCHEMBL21231854 | 0.77 | GAA (0.57) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL15647965 | 0.76 | CYP1A2 (0.71) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL909605 | 0.74 | CYP1A2 (0.68) | CYP1A2GAAPDE4APDE7AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445523-B2 | Dioxo-imidazolidine derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-21 | — | — | US | disclosed |
| EP-2401266-B1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE SOAT-1 ENZYME, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2012-11-28 | — | — | EP | disclosed |
| US-20120052096-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-03-01 | — | — | US | disclosed |
| EP-2401266-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097468-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052096-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | SOAT1, SOAT2, ODC1 | CYP1A2 412/4885GAA 49/4885PDE4A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.